[1]
|
Boberg, K.M., Chapman, R.W., Hirschfield, G.M., et al. (2011) Overlap Syndromes: The International Autoimmune Hepatitis Group (IAIHG) Position Statement on a Controversial Issue. Journal of Hepatology, 54, 374-385.
https://doi.org/10.1016/j.jhep.2010.09.002
|
[2]
|
尤红, 段维佳, 李淑香, 等. 原发性胆汁性胆管炎的诊断和治疗指南(2021) [J]. 临床肝胆病杂志, 2022, 38(1): 35-41.
|
[3]
|
Pells, G., Mells, G.F., Carbone, M., et al. (2013) The Impact of Liver Transplantation on the Phenotype of Primary Biliary Cirrhosis Patients in the UK-PBC Cohort. Journal of Hepatology, 59, 67-73.
https://doi.org/10.1016/j.jhep.2013.02.019
|
[4]
|
Chazouillères, O., Wendum, D., Serfaty, L., et al. (1998) Primary Biliary Cirrhosis-Autoimmune Hepatitis Overlap Syndrome: Clinical Features and Response to Therapy. Hepatology, 28, 296-301.
https://doi.org/10.1002/hep.510280203
|
[5]
|
European Association for the Study of the Liver (2017) EASL Clinical Practice Guidelines: The Diagnosis and Management of Patients with Primary Biliary Cholangitis. Journal of Hepatology, 67, 145-172.
https://doi.org/10.1016/j.jhep.2017.03.022
|
[6]
|
Zhang, W., De, D., Mohammed, K.A., et al. (2018) New Scoring Classification for Primary Biliary Cholangitis-Auto- immune Hepatitis Overlap Syndrome. Hepatology Communications, 2, 245-253. https://doi.org/10.1002/hep4.1148
|
[7]
|
Schulz, L., Sebode, M., Weidemann, S.A., et al. (2018) Variant Syndromes of Primary Biliary Cholangitis. Best Practice & Research Clinical Gastroenterology, 34-35, 55-61. https://doi.org/10.1016/j.bpg.2018.06.003
|
[8]
|
Yang, F., Wang, Q., Bian, Z., et al. (2015) Autoimmune Hepatitis: East Meets West. Journal of Gastroenterology and Hepatology, 30, 1230-1236. https://doi.org/10.1111/jgh.12952
|
[9]
|
Wang, Q., Selmi, C., Zhou, X., et al. (2013) Epigenetic Considerations and the Clinical Reevaluation of the Overlap Syndrome between Primary Biliary Cirrhosis and Autoimmune Hepatitis. Jour-nal of Autoimmunity, 41, 140-145.
https://doi.org/10.1016/j.jaut.2012.10.004
|
[10]
|
Kuiper, E.M., Zondervan, P.E. and Van Buuren, H.R. (2010) Paris Criteria Are Effective in Diagnosis of Primary Biliary Cirrhosis and Autoimmune Hepatitis Overlap Syndrome. Clinical Gastroenterology and Hepatology, 8, 530-534.
https://doi.org/10.1016/j.cgh.2010.03.004
|
[11]
|
马雄, 王绮夏, 肖潇, 等. 自身免疫性肝炎诊断和治疗指南(2021) [J]. 临床肝胆病杂志, 2022, 38(1): 42-49.
|
[12]
|
Lohse, A.W. (2011) Recognizing Autoimmune Hepatitis: Scores Help, but No More. Journal of Hepatology, 54, 193-194. https://doi.org/10.1016/j.jhep.2010.07.013
|
[13]
|
Wang, K., Li, Y., Pan, J., et al. (2022) Noninvasive Diagnosis of AIH/PBC Overlap Syndrome Based on Prediction Models. Open Medicine (Warsaw, Poland), 17, 1550-1558. https://doi.org/10.1515/med-2022-0526
|
[14]
|
Dalekos, G.N., Koskinas, J. and Papatheodoridis, G.V. (2019) Hel-lenic Association for the Study of the Liver Clinical Practice Guidelines: Autoimmune Hepatitis. Annals of Gastroenter-ology, 32, 1-23.
|
[15]
|
Czaja, A.J. (2016) Diagnosis and Management of Autoimmune Hepatitis: Current Status and Fu-ture Directions. Gut and Liver, 10, 177-203. https://doi.org/10.5009/gnl15352
|
[16]
|
Yang, F., Wang, Q., Wang, Z., et al. (2016) The Natural History and Prognosis of Primary Biliary Cirrhosis with Clinical Features of Autoimmune Hepatitis. Clinical Reviews in Allergy & Immunology, 50, 114-123.
https://doi.org/10.1007/s12016-015-8516-5
|
[17]
|
Manns, M.P., Woynarowski, M., Kreisel, W., et al. (2010) Budesonide Induces Remission More Effectively than Prednisone in a Controlled Trial of Patients with Autoimmune Hepatitis. Gastroenterology, 139, 1198-1206.
https://doi.org/10.1053/j.gastro.2010.06.046
|
[18]
|
Zhang, H., Yang, J., Zhu, R., et al. (2015) Combination Therapy of Ursodeoxycholic Acid and Budesonide for PBC-AIH Overlap Syndrome: A Meta-Analysis. Drug Design, Develop-ment and Therapy, 9, 567-574.
https://doi.org/10.2147/DDDT.S74515
|
[19]
|
Ozaslan, E., Efe, C., Heurgue-Berlot, A., et al. (2014) Factors Associ-ated with Response to Therapy and Outcome of Patients with Primary Biliary Cirrhosis with Features of Autoimmune Hepatitis. Clinical Gastroenterology and Hepatology, 12, 863-869. https://doi.org/10.1016/j.cgh.2013.09.021
|
[20]
|
Freedman, B.L., Danford, C.J., Patwardhan, V., et al. (2020) Treatment of Overlap Syndromes in Autoimmune Liver Disease: A Systematic Review and Meta-Analysis. Journal of Clinical Medicine, 9, 1449.
https://doi.org/10.3390/jcm9051449
|
[21]
|
Zhang, H., Li, S., Yang, J., et al. (2015) A Meta-Analysis of Ursodeox-ycholic Acid Therapy versus Combination Therapy with Corticosteroids for PBC-AIH-Overlap Syndrome: Evidence from 97 Monotherapy and 117 Combinations. Przegla̜d Gastroenterologiczny, 10, 148-155. https://doi.org/10.5114/pg.2015.51187
|
[22]
|
Tannous, M.M., Cheng, J., Muniyappa, K., et al. (2011) Use of Tacro-limus in the Treatment of Autoimmune Hepatitis: A Single Centre Experience. Alimentary Pharmacology & Therapeutics, 34, 405-407.
https://doi.org/10.1111/j.1365-2036.2011.04749.x
|
[23]
|
Aqel, B.A., Machicao, V., Rosser, B., et al. (2004) Effica-cy of Tacrolimus in the Treatment of Steroid Refractory Autoimmune Hepatitis. Journal of Clinical Gastroenterology, 38, 805-809.
https://doi.org/10.1097/01.mcg.0000139050.67178.be
|
[24]
|
Than, N.N., Wiegard, C., Weiler-Normann, C., et al. (2016) Long-Term Follow-Up of Patients with Difficult to Treat Type 1 Autoimmune Hepatitis on Tacrolimus Therapy. Scandinavian Journal of Gastroenterology, 51, 329-336.
https://doi.org/10.3109/00365521.2015.1095351
|
[25]
|
Terziroli Beretta-Piccoli, B., Mieli-Vergani, G. and Vergani, D. (2017) Autoimmune Hepatitis: Standard Treatment and Systematic Review of Alternative Treatments. World Journal of Gastroenterology, 23, 6030-6048.
https://doi.org/10.3748/wjg.v23.i33.6030
|
[26]
|
Haridy, J., Nicoll, A. and Sood, S. (2018) Methotrexate Therapy for Autoimmune Hepatitis. Clinical Gastroenterology and Hepatology, 16, 288-289. https://doi.org/10.1016/j.cgh.2017.07.003
|
[27]
|
Hindorf, U., Jahed, K., Bergquist, A., et al. (2010) Characterisation and Utility of Thiopurine Methyltransferase and Thiopurine Metabolite Measurements in Autoimmune Hepatitis. Journal of Hepatology, 52, 106-111.
https://doi.org/10.1016/j.jhep.2009.10.004
|
[28]
|
Pares, A., Shiffman, M., Vargas, V., et al. (2020) Reduction and Stabilization of Bilirubin with Obeticholic Acid Treatment in Patients with Primary Biliary Cholangitis. Liver Internation-al, 40, 1121-1129.
https://doi.org/10.1111/liv.14429
|
[29]
|
Bowlus, C.L., Pockros, P.J., Kremer, A.E., et al. (2020) Long-Term Obet-icholic Acid Therapy Improves Histological Endpoints in Patients with Primary Biliary Cholangitis. Clinical Gastroen-terology and Hepatology, 18, 1170-1178e6.
https://doi.org/10.1016/j.cgh.2019.09.050
|
[30]
|
Zhang, Y., Li, S., He, L., et al. (2015) Combination Therapy of Fenofibrate and Ursodeoxycholic Acid in Patients with Primary Biliary Cirrhosis Who Respond Incompletely to UDCA Monotherapy: A Meta-Analysis. Drug Design, Development and Therapy, 9, 2757-2766. https://doi.org/10.2147/DDDT.S79837
|
[31]
|
Corpechot, C., Chazouilleres, O., Rousseau, A., et al. (2018) A Pla-cebo-Controlled Trial of Bezafibrate in Primary Biliary Cholangitis. The New England Journal of Medicine, 378, 2171-2181. https://doi.org/10.1056/NEJMoa1714519
|
[32]
|
Liberal, R., De Boer, Y.S. andrade, R.J., et al. (2017) Expert Clinical Management of Autoimmune Hepatitis in the Real World. Alimentary Pharmacology & Therapeutics, 45, 723-732. https://doi.org/10.1111/apt.13907
|
[33]
|
Chung, Y., Rahim, M.N., Graham, J.J., et al. (2021) An Update on the Pharmacological Management of Autoimmune Hepatitis. Expert Opinion on Pharmacotherapy, 22, 1475-1488. https://doi.org/10.1080/14656566.2021.1895747
|
[34]
|
Burak, K.W., Swain, M.G., Santodomingo-Garzon, T., et al. (2013) Rituximab for the Treatment of Patients with Autoimmune Hepatitis Who Are Refractory or Intolerant to Standard Therapy. Canadian Journal of Gastroenterology, 27, 273-280. https://doi.org/10.1155/2013/512624
|
[35]
|
Than, N.N., Hodson, J., Schmidt-Martin, D., et al. (2019) Efficacy of Rituximab in Difficult-to-Manage Autoimmune Hepatitis: Results from the International Autoimmune Hepatitis Group. JHEP Reports, 1, 437-445.
https://doi.org/10.1016/j.jhepr.2019.10.005
|
[36]
|
Weiler-Normann, C., Schramm, C., Quaas, A., et al. (2013) In-fliximab as a Rescue Treatment in Difficult-to-Treat Autoimmune Hepatitis. Journal of Hepatology, 58, 529-534. https://doi.org/10.1016/j.jhep.2012.11.010
|
[37]
|
Chatrath, H., Allen, L. and Boyer, T.D. (2014) Use of Sirolimus in the Treatment of Refractory Autoimmune Hepatitis. The American Journal of Medicine, 127, 1128-1131. https://doi.org/10.1016/j.amjmed.2014.06.016
|
[38]
|
Ytting, H. and Larsen, F.S. (2015) Everolimus Treatment for Patients with Autoimmune Hepatitis and Poor Response to Standard Therapy and Drug Alternatives in Use. Scandinavi-an Journal of Gastroenterology, 50, 1025-1031.
https://doi.org/10.3109/00365521.2014.998271
|
[39]
|
Heneghan, M.A., Yeoman, A.D., Verma, S., et al. (2013) Autoimmune Hepatitis. The Lancet, 382, 1433-1444.
https://doi.org/10.1016/S0140-6736(12)62163-1
|
[40]
|
Halliday, N., Dyson, J.K., Thorburn, D., et al. (2020) Re-view Article: Experimental Therapies in Autoimmune Hepatitis. Alimentary Pharmacology & Therapeutics, 52, 1134-1149. https://doi.org/10.1111/apt.16035
|
[41]
|
Aguilar, M.T. and Carey, E.J. (2018) Current Status of Liver Transplantation for Primary Biliary Cholangitis. Clinical Liver Disease, 22, 613-624. https://doi.org/10.1016/j.cld.2018.03.011
|
[42]
|
Li, Y., Yan, L., Wang, R., et al. (2022) Serum Immunoglobulin G Levels Predict Biochemical and Histological Remission of Autoimmune Hepatitis Type 1: A Single-Center Experience and Literature Review. Clinical Reviews in Allergy & Immunology, 62, 292-300. https://doi.org/10.1007/s12016-021-08833-w
|
[43]
|
Van Gerven, N.M., Verwer, B.J., Witte, B.I., et al. (2013) Re-lapse Is Almost Universal after Withdrawal of Immunosuppressive Medication in Patients with Autoimmune Hepatitis in Remission. Journal of Hepatology, 58, 141-147.
https://doi.org/10.1016/j.jhep.2012.09.009
|